Director Robert V. Baumgartner filed a Form 4 with the SEC on November 2, 2026, disclosing the acquisition of 2,750 shares of BIO-TECHNE Corp common stock on October 29, 2026, along with a new stock option grant covering 3,777 shares.

Key Highlights

  • Acquisition: Robert V. Baumgartner acquired 2,750 shares of BIO-TECHNE Corp common stock on October 29, 2026, at a price of $0.
  • Post-transaction holdings: Following the transaction, Baumgartner directly beneficially owns 59,634 shares of common stock.
  • New option grant: A stock option to purchase 3,777 shares of common stock was reported, with an exercise price of $60.96, exercisable from October 29, 2026, and expiring October 30, 2035.
  • Total options held: Baumgartner holds stock options across nine separate grants, covering a combined 51,381 shares of common stock, with exercise prices ranging from $31.26 to $128.81.
  • Issuer and exchange: The issuer is BIO-TECHNE Corp, trading on NASDAQ:TECH.
  • Filer role: Baumgartner is identified in the filing as a Director of BIO-TECHNE Corp.

BIO-TECHNE Director Baumgartner Reports October 2026 Share and Option Awards

According to the Form 4 filed on November 2, 2026, Robert V. Baumgartner, a Director of BIO-TECHNE Corp (NASDAQ:TECH), acquired 2,750 shares of common stock on October 29, 2026, at a reported price of $0 per share, a transaction coded "A" indicating an acquisition. Following this transaction, the filing reports that Baumgartner directly beneficially owns 59,634 shares of common stock.

The filing also discloses a new stock option grant in Table II. The option, with an exercise price of $60.96 per share, covers 3,777 shares of common stock, became exercisable on October 29, 2026, and expires on October 30, 2035. No consideration for this option grant was listed. This brings Baumgartner's reported stock option holdings to nine separate grants. The other eight previously reported options carry exercise prices of $31.26, $44.96, $50.41, $63.92, $128.81, $73.94, $61.51, and $68.37, with expiration dates ranging from October 26, 2027, through October 24, 2034.

The Form 4 was signed by Andrew Nick as Attorney-in-Fact for Robert V. Baumgartner pursuant to a power of attorney previously filed. All reported securities are held directly. No indirect beneficial ownership was reported in this filing.

What Was Disclosed

The filing disclosed Director Robert V. Baumgartner's acquisition of 2,750 shares of BIO-TECHNE Corp common stock at $0 on October 29, 2026, bringing his direct beneficial ownership to 59,634 shares, and a new stock option grant for 3,777 shares at an exercise price of $60.96.